Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-01-24
2002-09-24
Owens, Amelia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S403000
Reexamination Certificate
active
06455577
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel flavanone derivatives; a process for preparing same; a pharmaceutical composition containing same for treating or preventing an elevated blood lipid level-related disease, inhibiting the activity of acyl-CoA:cholesterol-O-acyltransferase(ACAT) and inhibiting the activity of 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase.
BACKGROUND OF THE INVENTION
In recent years, coronary artery diseases, e.g., atherosclerosis and hypercholesterolemia, have increasingly become a major cause of deaths. It has been reported that an elevated plasma cholesterol level causes the deposition of fat, macrophages and foam cells on the wall of blood vessels, such deposit leading to plaque formation and then to atherosclerosis(Ross, R.,
Nature,
362, 801-809(1993)). One of the methods for decreasing the plasma cholesterol level is alimentotherapy to reduce the ingestion of cholesterol and lipids. Another method is to inhibit the absorption of cholesterol by inhibiting enzymes involved therein.
Acyl-CoA:cholesterol-O-acyltransferase(ACAT) promotes the esterification of cholesterol in blood. Foam cells are formed by the action of ACAT and contain a large amount of cholesterol ester carried by low density lipoproteins. The formation of foam cells on the wall of artery increases with the ACAT activity, and, accordingly, an inhibitor of ACAT may also be an agent for preventing atherosclerosis. Further, it has been reported that the blood level of LDL-cholesterol can be reduced by inhibiting the ACAT activity(Witiak, D. T. and D. R. Feller(eds.),
Anti-Lipidemic Drugs: Medicinal, Chemical and Biochemical Aspects
, Elsevier, pp159-195(1991)).
Therefore, numerous efforts have been made to develop medicines which inhibit ACAT activity; and, as a result, several compounds isolated from the cultures of various microorganisms have been reported. Examples of such compounds include pyripyropenes isolated from the culture of Aspergillus fumigatus(S. Omura et al.,
J. Antibiotics,
46, 1168-1169(1993)) and Acaterin isolated from Pseudomonas sp.(S. Nagamura et al.,
J. Antibiotics,
45, 1216-1221(1992)).
Further, it has been reported that hypercholesterolemia can be treated effectively by reducing the rate of cholesterol biosynthesis through the inhibition of HMG-CoA reductase which mediates the synthesis of mevalonic acid, an intermediate in a biosynthesis of sterol or isoprenoids(
Cardiovascular Pharmacology
, William W. Parmley and Kanu Chatterjee Ed, Wolf Publishing, pp8.6-8.7, 1994).
Accordingly, numerous efforts have been made to develop medicines to inhibit HMG-CoA reductase; and, as a result, several compounds derived from
Penicillium
sp. and
Aspergillus
sp. have been commercialized. Specifically, Lovastatin® and Simvastatin® developed Merck Co., U.S.A., and Pravastatin® developed by Sankyo Co., Japan, have been commercialized(C. D. R. Dunn,
Stroke: Trends, Treatment and Markets
, SCRIPT Report, PJB Publications Ltd., 1995). However, these medicines are very expensive and a long-term administration thereof is known to induce an adverse side effect of increasing creatine kinase in the liver. Accordingly, there has continued to exist a need to develop an inexpensive and non-toxic inhibitor of HMG-CoA reductase.
On the other hand, deterioration of hepatic functions may occur due to an excessive intake of alcohol or foods having a high lipid content, or an infection of hepatitis B or C virus, and it may develop into hepatitis, hepatocirrhosis or hepatic cancer. In particular, the excessive intake of fat-containing foods and alcohol causes fatty liver wherein a large amount of lipids is deposited in the liver tissue and the levels of serum GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) and &ggr;-GTP(&ggr;-glutamyl transpeptidase) are elevated(T. Banciu et al.,
Med. Interne.,
20, 69-71(1982); and A. Par et al.,
Acta. Med. Acad. Sci. Hung.,
33, 309-319(1976)). Accordingly, there has continued to exist a need to develop non-toxic agents for preventing and treating elevated blood lipid level-related diseases, and hepatic diseases.
The present inventors have reported that naringenin and hesperetin, which are the aglycons of naringin and hesperidin found in lemons, grapefruits, tangerines and oranges(Citrus sinensis), have activities for inhibiting hyperlipidemia and atherosclerosis (U.S. Pat. Nos. 5,877,208 and 5,763,414).
The present inventors have continued to screen compounds having the flavanone core structure; and have discovered that certain novel flavanone derivatives have enhanced activity in treating or preventing elevated blood lipid level-related diseases, inhibiting an activity of acyl-CoA:cholesterol-O-acyltransferase(ACAT) and inhibiting an activity of 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide novel flavanone derivatives.
It is another object of the present invention to provide a process for the preparation of the inventive flavanone derivatives.
It is a further object of the present invention to provide a pharmaceutical composition for treating or preventing an elevated blood lipid level-related disease, inhibiting an activity of acyl-CoA:cholesterol-O-acyltransferase(ACAT) and inhibiting an activity of 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase.
It is a further object of the present invention to provide a method for treating or preventing an elevated blood lipid level-related disease, inhibiting an activity of acyl-CoA:cholesterol-O-acyltransferase(ACAT) and inhibiting an activity of 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) In accordance with the present invention, there is provided a novel compound of formula (I):
wherein,
R
1
is R
5
or R
6
CO group;
R
2
is H or R
6
CO group;
R
3
is H, CH3, R
5
or R
6
CO group;
R
4
is H, OH, OR
5
or R
6
COO group;
R
5
is a C
2-5
alkyl group substituted with a phenyl group optionally having one or more substituents selected from the group consisting of C
1-3
alkyl, OH, Cl and NO
2
; a C
1-5
alkyl group substituted with a naphthyl group optionally having one or more substituents selected from the group consisting of C
1-3
alkyl, OH, Cl and NO
2
; a C
10-18
alkyl; or a C
10-18
alkenyl group; and
R
6
is a C
10-18
alkenyl group; or an aryl group optionally having one or more substituents selected from the group consisting of C
1-3
alkyl, OH, Cl or NO
2
.
REFERENCES:
Krishnamurty, et. al., “On the first one-pot general synthesis of novel 3-benzal-2,3-dihydro-4H-[1]benzopyran-4-ones” CA 112:98248 (1990).
Bok Song-Hae
Choi Myung-Sook
Choi Yang-Kyu
Hyun Byung-Hwa
Jeong Tae-Sook
Katten Muchin Zavis & Rosenman
Korea Research Institute of Bioscience and Biotechnology
Owens Amelia
LandOfFree
Flavanone derivatives and composition for preventing or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Flavanone derivatives and composition for preventing or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flavanone derivatives and composition for preventing or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2855140